Systemic therapy for malignant melanoma;Medikamentöse therapie des malignen melanoms

Hautarzt

Volumn 63, Issue 11, 2012, Pages 885-898

  Rudolph, B M ^a   Groffik, A ^a   Stanger, C ^a   Loquai, C ^a   Grabbe, S ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Anti CTLA4 antibody; BRAF inhibitor; Immunotherapy; Malignant melanoma; Molecular targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE INHIBITOR;

ARTICLE; CANCER SURVIVAL; HUMAN; IMMUNOMODULATION; LONG TERM CARE; MELANOMA; OVERALL SURVIVAL; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MELANOMA; MOLECULAR TARGETED THERAPY; SKIN NEOPLASMS;

EID: 84871420934     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-012-2447-3     Document Type: Article

References (28)

1. Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147
2. Fong L, Small EJ (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275-5283
3. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
4. Mocellin S, Pasquali S, Rossi CR et al (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-Analysis. J Natl Cancer Inst 102:493-501
5. Kirkwood JM, Strawderman MH, Ernstorff MS et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17
6. Eggermont A, Suciu S, Testori A et al (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218-225
7. Garbe C, Schadendorf D, Stolz W et al (2007) ADO Kurzleitlinie -malignes Melanom der Haut
8. Kleeberg UR, Suciu S, Bröcker EB et al (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial:rIFN-A2b versus rIFN-g versus ISCADOR M1 versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40:390-402
9. Eigentler TK, Radny R, Hauschild A et al (2008) Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 18:353-358
10. Veronesi U, Adamus J, Aubert C (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913-916
11. Davies H, Bignell GF, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
12. Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
13. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
14. Chapman PB, Hausschild A, Robert C et al (2012) Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAF V600E-mutated melanoma. J Clin Oncol 30(Suppl15):8502
15. Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365
16. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600 -mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714
17. Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114
18. Ascierto PA, Berking C, Agarwala SS et al (2012) Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harbouring BRAFV600 or NRAS mutations. J Clin Oncol 30(Suppl 15):8511
19. Garrido MC, Bastian BC (2010) KIT as a therapeutic target in melanoma. J Invest Dermatol 130:20-27
20. Hauschild A, Agarwala SS, Trefzer U et al (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823-2830
21. Hodi FS, O'Day SJ, McDermott SF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
22. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
23. Sparano J, Fisher R, Sunderland M et al (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon-Alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969-1977
24. Sasse AD, Sasse EC, Clark LG et al (2007) Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev (1):CD005413
25. Keilholz U, Punt CJA, Gore M et al (2005) Dacarbazine, cisplatin, and interferon-Alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23:6747-6755
26. Eigentler TK, Caroli UM, Radny P et al (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759
27. Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK Inhibition in melanoma with BRAF V600 mutations. N Engl J Med [Epub ahead of print]
28. Grob JJ, Dreno B, Salmoniere P de la et al (1998) Randomized trial of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351:1905-1910